Brokers Offer Predictions for Enanta Pharmaceuticals Inc’s Q3 2019 Earnings (ENTA)

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) – Oppenheimer lifted their Q3 2019 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Wednesday, May 8th. Oppenheimer analyst J. Olson now forecasts that the biotechnology company will post earnings per share of ($0.04) for the quarter, up from their previous forecast of ($0.07). Oppenheimer also issued estimates for Enanta Pharmaceuticals’ Q4 2019 earnings at $0.46 EPS, FY2020 earnings at ($0.39) EPS, FY2021 earnings at ($2.47) EPS, FY2022 earnings at ($3.97) EPS and FY2023 earnings at ($3.14) EPS.

Several other analysts have also recently commented on the stock. Berenberg Bank upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a research report on Tuesday, April 23rd. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 24th. Finally, Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $114.40.



Shares of Enanta Pharmaceuticals stock opened at $87.25 on Monday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 25.07 and a beta of 1.30. Enanta Pharmaceuticals has a 52 week low of $64.08 and a 52 week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The firm had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. During the same quarter in the previous year, the company posted $0.61 EPS. Enanta Pharmaceuticals’s revenue was down 10.0% on a year-over-year basis.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Vanguard Group Inc increased its position in shares of Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after buying an additional 330,374 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after buying an additional 330,374 shares in the last quarter. Marshall Wace North America L.P. increased its position in shares of Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after buying an additional 207,326 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Enanta Pharmaceuticals by 17.0% in the 1st quarter. Janus Henderson Group PLC now owns 874,397 shares of the biotechnology company’s stock valued at $83,522,000 after buying an additional 126,804 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $7,106,000. Institutional investors and hedge funds own 87.19% of the company’s stock.

In other Enanta Pharmaceuticals news, VP Yat Sun Or sold 10,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $103.53, for a total transaction of $1,035,300.00. Following the completion of the sale, the vice president now owns 304,763 shares in the company, valued at approximately $31,552,113.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director George Golumbeski sold 9,280 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $103.65, for a total transaction of $961,872.00. Following the completion of the sale, the director now owns 9,280 shares of the company’s stock, valued at approximately $961,872. The disclosure for this sale can be found here. Insiders have sold a total of 20,826 shares of company stock valued at $2,150,473 in the last quarter. Corporate insiders own 11.35% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Article: Quick Ratio

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.